Using Analytics to Improve Care Management

Robert A. Crossey, DO Francis R Colangelo, MD

October 9, 2019



Premier Medical Associates

Eastern suburbs Pittsburgh, PA

Formed 1993


100 providers

1:1 PCP to specialists

7 adult PCP locations

Part of Highmark Health/ Allegheny Health network IDFS

Allscripts Touchworks



Provided care to more than 100,000 lives
All adult and pediatric offices have
Level 3 PCMH certification



2018

377,000 patient visits

Specialties

Allergy and immunology

Internal Medicine

Audiology

Laboratory Services

Behavioral Health

Neurology

Cardiology

Ophthalmology

Electrophysiology

Optometry

Dermatology

Pain Management

Ear, Nose & Throat

Pediatrics

Family Medicine

Pulmonology

Gastroenterology

Radiology

General and Breast

Surgery

Rheumatology


Hospitalists

Sleep Medicine

Infectious Disease




AAP: Patients by age and gender






AAP: Patients by chronic disease profile





AAP: Patients by categorized BMI









Winning patients through value-based care


- Emphasis on reducing the incidence of diseases that are amenable to screening and prevention
- Emphasis on improving control of chronic diseases
- Use of advanced analytics to risk stratify and focus care coordination efforts

Value =

Access + Differentiated Experience + Outcomes (quality and safety)

Cost





"It now takes an average of 17 years for new knowledge generated by randomized controlled trails to be incorporated into practice, and even then, application is highly uneven."







PMA engagement and management

Heart failure | Prediabetes | Diabetes



HEART FAILURE BY THE NUMBERS

5.1 MILLION PEOPLE

OVER HALF
OF HEART FAILURE COSTS
ARE DUE TO HOSPITALIZATION?



\$165K EXPECTED
TO BE WITHHELD PER HOSPITAL
BY MEDICARE READMISSION PENALTY


Modern Healthcare, 2015

EVEN WITH DAILY SELF-MONITORING

25% OF HEART FAILURE PATIENTS ARE READMITTED TO THE HOSPITAL WITHIN 30 DAYS

50% OF HEART FAILURE PATIENTS ARE READMITTED TO THE HOSPITAL WITHIN 6 MONTHS







Heart failure

First disease state that we employed an advanced analytics/population health software:

- To identify gaps in proper prescribing
- To risk stratify patients to direct care coordination efforts

Correct prescribing			
	12/31/15	9/30/16	
ACE/ARB	75%	95.2%	
Correct β-blocker	76%	97.7%	




Using predictive analytics to risk stratify...


CHF: Pts by Likelihood of CHF-related Hospitilization w/ in 6 months











Circulation, 139(19), 2285-2288.




PMA ARNI use

As of	ARNI prescribed	Potential use	% compliance
12/31/16	29	403	7.2%
12/31/18	70	399	17.5%
6/30/19	82	408	20.1%




PREDIABETES

COULD IT BE YOU?



84.1 million
American adults —
more than
1 out of 3 — have
prediabetes



people with prediabetes don't know they have it



The New England Journal of Medicine

Copyright © 2002 by the Massachusetts Medical Society

VOLUME 346

FEBRUARY 7, 2002

NUMBER 6



REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE INTERVENTION OR METFORMIN

DIABETES PREVENTION PROGRAM RESEARCH GROUP*

ABSTRACT

Background Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors — elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle — are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes.

Methods We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The mean age of the participants was 51 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 34.0; 68 percent were women, and 45 percent were members of minority groups.

Results The average follow-up was 2.8 years. The incidence of diabetes was 11.0, 7.8, and 4.8 cases per 100 person-years in the placebo, metformin, and lifestyle groups, respectively. The lifestyle intervention reduced the incidence by 58 percent (95 percent contents)

YPE 2 diabetes mellitus, formerly called non-insulin-dependent diabetes mellitus, is a serious, costly disease affecting approximately 8 percent of adults in the United States. Treatment prevents some of its devastating complications 2,3 but does not usually restore normoglycemia or eliminate all the adverse consequences. The diagnosis is often delayed until complications are present. Since current methods of treating diabetes remain inadequate, prevention is preferable. The hypothesis that type 2 diabetes is preventable 5,6 is supported by observational studies and two clinical trials of diet, exercise, or both in persons at high risk for the disease 7,8 but not by studies of drugs used to treat diabetes.

The validity of generalizing the results of previous prevention studies is uncertain. Interventions that work in some societies may not work in others, because social, economic, and cultural forces influence diet and exercise. This is a special concern in the United States, where there is great regional and ethnic diversity in lifestyle patterns and where diabetes is especially frequent in certain racial and ethnic groups, including American Indians, Hispanics, African Amer-



Metformin for prediabetes

NHANES 2005 to 2012	Commercially insured 2010 to 2012
< 1% use	3.7% use


Annals of internal medicine, 162(8), 542-548. | Diabetes Care, dc161509.




Heterogeneity of treatment effect:

Diabetes prevention program study

Intensive lifestyle intervention



Metformin



Value of a multivariable model


In the lowest-risk quartile, about 15% of patients: A1c ≥ 6.0

In the highest-risk quartile, more than 25% of patients: A1c < 6.0

http://www.pcori.org/research-in-action/moving-beyond-averages



Calculator variables





Predictive model results

(as displayed in EHR at Premier Medical Associates)

Interpretation: Low Risk Patient			
Treatment	Relative Risk Reduction	Number Needed to Treat	
	(RRR)	(NNT)	
Usual Care	Reference	N/A	
Metformin	20%	91.4	
DPP Lifestyle	58%	31.5	
	Treatment Usual Care Metformin DPP	Treatment Relative Risk Reduction (RRR) Usual Care Reference Metformin 20% DPP 58%	

Add to Chart

Interpretation: High Risk Patient				
Predicted Risk of Type 2 Diabetes at 3 Years	Treatment	Relative Risk Reduction (RRR)	Number Needed to Treat (NNT)	
55.7 %	Usual Care	Reference	N/A	
24.5 %	Metformin	56%	4	
23.4 %	DPP Lifestyle	58%	4	
			Add to Chart	



PMA experience-reach of project

	5/1/18 — 8/31/19
Total prediabetes	2518
Calculation completed	1881
Percent with calculation	74.7%




PMA risk stratification

Risk stratification	n=	%
High risk	901	47.9%
Medium risk	921	48.5%
Low risk	68	3.6%



Of the 722 high risk patients ...



Metformin

- 45 were on it before 5/1/18 (6.2%)
- 118 were started on it after 5/1/18 (16.3%)

Diabetes Prevention Program


- 0 were referred before 5/1/18 (0%)
- 378 were referred after 5/1/18 (52.3%)



Interventions vs. Risk

Risk stratification	Intervention ordered
High risk	75.2%
Medium risk	20.6%
Low risk	7.3%





Potential cost savings

Intermountain Insurance Plan saves \$3,500 per person per year; development of diabetes is averted or delayed.

CMS Office of the Actuary estimates a savings of \$2,650 over 15 months for Medicare beneficiaries participating in a DPP lifestyle program.

Why a bundle measure?



All-or-None Measurement Raises the Bar on Performance

Thomas Nolan, PhD

Donald M. Berwick, MD, MPP

HE PURSUIT OF EVIDENCE-BASED MEDICINE IS NOW AT the core of the agenda for improving health care in the United States. All major quality measurement systems use science-based indicators of proper processes of care, such as the ORYX measures of the Joint Commission on Accreditation of Healthcare Organizations, the Health Employer Data and Information Sets measures of the National Committee on Quality Assurance, the measures used by the Quality Improvement Organizations under contract with the Centers for Medicare & Medicaid Services, and at least 70 of the 179 measures in the 2004 National Health Care Quality Report from the Agency for Healthcare Research and Quality.

Often, several individual performance measures are use to assess care of the same condition. For example, a recer summary of data on the Joint Commission on Accredita

Option 2: Composite Measurement

Performance on the provision of several elements of care is reported by computing a percentage across all patients and criterion indicators. For example, for the 4 elements of pneumonia care (excluding the continuous variable of time to treatment), a composite measure of performance can be computed by summing the numerators for each measure across the population of interest to create a composite numerator (all the care that was given), summing the denominators for each measure to form a composite denominator (all the care that should have been given), and reporting the ratio (the percentage of all the needed care that was given). This approach to measurement gives partial credit for incomplete care of an individual patient. If a patient receives 3 of the 4 recommended care elements, a hospital whose performance is being assessed with such a composite measure gets credit for delivering 3 elements. The Centers for Medicare & Medicaid Services uses composite measurement of this type in its Hospital Quality Incentive Demonstration Project.

JAMA. 2006;296(4):392-393. doi:10.1001/jama.296.4.392-a



Why a bundle measure?

- What would you want for yourself or your family member?
- Reflects the patient's perspective—holistic view
 - Address all key risk factors or care needs
- Encourages system perspective—no dropped balls
 - Are all contributors to the care process working together?
- More sensitive scale for assessing improvement
 - Amplifies variation in care process
 - Also amplifies errors in measurement





PMA diabetes bundle improvement

Measure	As of 12/31/15	As of 6/30/17	As of 6/30/18	As of 6/30/19
HGBa1c control rate (<8%)	70.6%	72.0%	74.8%	73.9%
BP control rate	78.8%	80.5%	81.5%	85.1%
Medical attention to kidney disease	88.6%	90.3%	91.8%	90.3%
Statin prescribing rates	68.9%	78.3%	84.9%	85.2%
D4 control bundle	40.7%	47.2%	49.2%	51.7%



